Investigational drug · Phase 3
BPN14770
Also called: zatolmilast
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fragile X Syndrome, Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
14
Any phase or sponsor naming "BPN14770"
First trial start
2022
Mar 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BPN14770", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fragile X Syndrome
- Jordan's Syndrome
- PPP2R5D Neurodevelopmental Disorder
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BPN14770" as an intervention, largest first.
- An Open-Label Extension Study of BPN14770 in Subjects With Fragile X SyndromePivotal-lookingActive, not recruiting
Tetra Discovery PartnersIndustry
NCT05367960 · 314 participants · Start Nov 1, 2022 · Primary completion Sep 30, 2027
Drug: Zatolmilast/ BPN14770 · For: Fragile X Syndrome
Sites: Irvine, California; Orange, California; Sacramento, California · 17 sites in all
- Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's SubjectsPivotal-lookingCompleted
Tetra Discovery PartnersIndustry
NCT03817684 · 255 participants · Start Apr 30, 2019 · Primary completion Feb 4, 2020
Drug: BPN14770; Placebo · For: Alzheimer's Disease
Sites: Gilbert, Arizona; Bellflower, California; Costa Mesa, California · 41 sites in all
- A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromePivotal-lookingCompleted
Tetra Discovery PartnersIndustry
NCT05358886 · 171 participants · Start Nov 1, 2022 · Primary completion Jul 18, 2025
Drug: BPN14770/ zatolmilast; Placebo · For: Fragile X Syndrome
Sites: Irvine, California; Orange, California; Sacramento, California · 17 sites in all
- A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X SyndromePivotal-lookingCompleted
Tetra Discovery PartnersIndustry
NCT05163808 · 163 participants · Start Mar 29, 2022 · Primary completion Sep 2, 2025
Drug: zatolmilast; Placebo · For: Fragile X Syndrome
Sites: Irvine, California; Orange, California; Sacramento, California · 17 sites in all
- A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female SubjectsCompleted
Tetra Discovery PartnersIndustry
NCT02840279 · 77 participants · Start Jun 2016 · Primary completion Nov 2016
Drug: BPN14770; Placebo · For: Alzheimer's Disease
Sites: Kalamazoo, Michigan
Tetra Discovery PartnersIndustry
NCT03030105 · 38 participants · Start Jan 2017 · Primary completion May 2017
Drug: BPN14770; BPN14770 placebo and 4 more · For: Alzheimer Disease
Sites: Austin, Texas
Tetra Discovery PartnersIndustry
NCT02648672 · 32 participants · Start Dec 2015 · Primary completion Feb 2016
Drug: BPN14770; Placebo · For: Alzheimer's Disease
Sites: Kalamazoo, Michigan
ShionogiIndustry
NCT07018492 · 32 participants · Start Aug 30, 2025 · Primary completion Nov 26, 2025
Drug: BPN14770 · For: Hepatic Impairment
Sites: Miami, Florida; Orlando, Florida; San Antonio, Texas
- Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])Active, not recruiting
ShionogiIndustry
NCT06717438 · 30 participants · Start May 13, 2025 · Primary completion Dec 31, 2027
Drug: BPN14770; Placebo · For: Jordan's Syndrome; PPP2R5D Neurodevelopmental Disorder
Sites: Chicago, Illinois; Boston, Massachusetts; Seattle, Washington
Tetra Discovery PartnersIndustry
NCT03569631 · 30 participants · Start Jul 9, 2018 · Primary completion Jul 31, 2020
Drug: BPN14770; Placebo · For: Fragile X Syndrome; FXS; Fra(X) Syndrome
Sites: Chicago, Illinois
Newest research
PubMed records naming it or its code names, newest first.
- Jiao-tai-wan suppresses ferroptosis induced by heart-kidney disharmony insomnia by regulating the PDE4D/BDNF signaling pathway.
Ye W, Lin Z, You Z, et al. · Phytomedicine 2026
- The Emerging Role of Phosphodiesterase Inhibitors in Fragile X Syndrome and Autism Spectrum Disorder.
Thomas SD, Mohammed HA, Hamad MIK, et al. · Pharmaceuticals (Basel) 2025
- ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers.
Norris JE, Berry-Kravis EM, Harnett MD, et al. · Transl Psychiatry 2025
- Individual contribution of PDE4B and PDE4D subfamilies to the prevention of object location memory impairments induced by sleep deprivation.
Zhao H, Blokland A, Prickaerts J, et al. · Learn Mem 2025
- Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy.
Zhu Z, Guan Q, Xu B, et al. · Br J Pharmacol 2025
- Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome.
Norris JE, Berry-Kravis EM, Harnett MD, et al. · Mol Autism 2024
Also in development for Fragile X Syndrome
- SPG601CodabakalnerPhase 32 trials
Spinogenix · Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD), Fragile X Syndrome
- cannabidiol as a clear that can be applied to the skinZYN002, transdermal deliveryPhase 31 trial
Harmony Biosciences Management, Inc. · Fragile X Syndrome, Fragile X Syndrome (FXS)
- CTH120Phase 21 trial
Connecta Therapeutics, S.L. · Fragile X Syndrome (FXS), Fragile X Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.